Company / Inventory
Sarepta Therapeutics Inventory History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$914.7M
FY2025
5-year range
$186.2M / $914.7M
FY2021-FY2025
Trend
+22.0%
vs FY2024
Sector context
#20 of 105
Health Care
What the data says
Sarepta Therapeutics's inventory of $915M is higher than 81% of companies in the Health Care sector (FY2025). Inventory has increased for 4 consecutive years, from $186M in FY2021 to $915M in FY2025.
Based on SEC 10-K filings.
$915M in FY2025 with a 5-year CAGR of +31.6%. Top quartile in the Health Care sector.
Improved from $323M to $915M over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- +64.9%
- 5-Year CAGR
- +31.6%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 105This company $914.7M Sector average $885.3M
▼
+3.3% above sector average
Key checks
Key Insights
- Sarepta Therapeutics's inventory has grown for 4 consecutive years.
- 5-year CAGR of +31.6%, indicating consistent growth.
- In FY2025, inventory increased 22.0% year-over-year.
- Ranks #20 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $914.7M | +22.0% |
| FY2024 | $750.0M | +132.3% |
| FY2023 | $322.9M | +58.3% |
| FY2022 | $204.0M | +9.5% |
| FY2021 | $186.2M | -19.7% |
| FY2020 | $232.0M | +35.3% |
| FY2019 | $171.4M | +36.6% |
| FY2018 | $125.4M | +50.0% |
| FY2017 | $83.6M | +552.5% |
| FY2016 | $12.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026